Search global stocks & ETFs...Ctrl K
Learn Mode
United Therapeutics CorpUTHR
$544.92
$2.26 (0.416%)
$544.93
$0.01 (0.002%)
UTHR
Stock Profile
07-28
Recommended Metric
Score Card
Explore Scores Tab
3.81
Good
Valuation Score
Key Score
5.00
Very Good
Management
3.00
Average
Growth
3.00
Average
Profitability
2.00
Bad
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.Read More